Rollover trial tests continued sitravatinib combo for advanced cancers

NCT ID NCT04887870

Completed Disease control Sponsor: Mirati Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study looked at the safety and effectiveness of continuing sitravatinib, a targeted cancer drug, either alone or combined with other therapies like nivolumab or pembrolizumab, in people with advanced or metastatic solid tumors. It enrolled 52 patients who were already benefiting from sitravatinib in a previous study. The main goal was to track side effects and how long the cancer stayed under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sitravatinib (a targeted therapy) alone or combined with other anticancer drugs like nivolumab or pembrolizumab
What this could lead to: If successful, this could show that continuing sitravatinib-based treatment is safe and may help control advanced cancers for longer.
What could go wrong: This is a small rollover study (52 people) that only included patients already benefiting from treatment. Results may not apply to all patients, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID MALIGNANCIES

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Local Institution - 516-014-001

Austin, Texas, 78758, United States
Local Institution - 516-014-002

Boston, Massachusetts, 02215, United States
Local Institution - 516-014-004

Columbus, Ohio, 43210, United States
Local Institution - 516-014-005

Minneapolis, Minnesota, 55455, United States
Local Institution - 516-014-011

Albany, New York, 12208, United States
Local Institution - 516-014-013

Houston, Texas, 77030, United States
Local Institution - 516-014-029

Goshen, Indiana, 46526, United States
Memorial Sloan Kettering Cancer Center - Arnold and Marie Schwartz Cancer Research Building

New York, New York, 10065, United States
NEXT Virginia

Fairfax, Virginia, 22031, United States
Rocky Mountain Cancer Centers - Littleton

Littleton, Colorado, 80218, United States
USOR - Texas Oncology Northeast Texas - Denison

Denison, Texas, 75020, United States
Urology Cancer Center and GU Research Network

Omaha, Nebraska, 68130, United States